ASB1

Across TCGA pan-cancer cohorts, ASB1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ASB1 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ASB1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ASB1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, GBM, and PDAC are the cancer types where ASB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.775	0.215	<.001	46	view →
GBM	DFS	Tertile	All	0.190	0.544	<.001	10	view →
PDAC	DFS	Tertile	III,IV	0.216	0.872	.024	3	view →
HNSC	DFS	Median	IV	0.873	1.000	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ASB1–LUAD (DFS)

Open the LUAD breakdown →